• Explore /
  • Poster
  • / Phase II clinical trial of camrelizumab combined with famitinib for advanced acral and mucosal melanoma.

Phase II clinical trial of camrelizumab combined with famitinib for advanced acral and mucosal melanoma.

Abstract Poster

Authors

null

Lili Mao

Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Melanoma and Sarcoma, Peking University Cancer Hospital and Institute, Beijing, China

Lili Mao , Lu Si , Caili Li , Xue Bai , Jie Dai , Xiaoting Wei , Yan Kong , Chuanliang Cui , Zhihong Chi , Xinan Sheng , Bin Lian , Xuan Wang , Bixia Tang , Siming Li , Xieqiao Yan , Li Zhou , Juan Li , Xiaowen Wu , Huajun Li , Jun Guo

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2023 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Melanoma/Skin Cancers

Track

Melanoma/Skin Cancers

Sub Track

Advanced/Metastatic Disease

Clinical Trial Registration Number

NCT05051865

Citation

J Clin Oncol 41, 2023 (suppl 16; abstr 9550)

DOI

10.1200/JCO.2023.41.16_suppl.9550

Abstract #

9550

Poster Bd #

313

Abstract Disclosures

Similar Posters

First Author: Tae-Yong Kim

First Author: Dongmei Ji

First Author: Lorenzo Pilla

First Author: Koichi Azuma